Serological diagnosis of infectious mononucleosis using three anti-Epstein-Barr virus recombinant ELISAs

Färber, I; Wutzler, Peter; Wohlrabe, Peter; Wolf, Hans; Hinderer, Walter; Sonneborn, H.‐H.

doi:10.1016/0166-0934(93)90041-o

Cited by 37 publications

(16 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The EA IgM analyses with positive results were further categorised as significantly positive (optical density ≥0.5) and positive with uncertain significance, weak reactivation (OD ≥cutoff but <0.5). The sensitivity when using all the three tests from Biotest Diagnostics has been estimated to 99–100% and the specificity to 86–99% 26,27 …”

Section: Methodsmentioning

confidence: 99%

Epstein–Barr virus infection during pregnancy and the risk of adverse pregnancy outcome

Eskild

Bruu

Stray‐Pedersen

et al. 2005

BJOG

View full text Add to dashboard Cite

Objectives To study the association between Epstein -Barr virus (EBV) antibody status in early pregnancy and pregnancy outcomes including fetal death, length of gestation and fetal weight and length at birth. Design Nested control study.Setting Population based health registers.Population The source population comprised 35,940 pregnant women. Cases were all (280) women with fetal death and a random sample of 940 women with a live born child. Method Information on pregnancy outcome was obtained from the Norwegian Medical Birth Registry. Serum samples from the first trimester were tested for EBV antibodies. In women seronegative for EBV, further serum from late pregnancy was analysed to detect seroconversion. Main outcome measures Vital status, length of gestation, weight and length at birth.Results There was no association between EBV antibody status and fetal death. Women with significant EBV reactivation had a significantly shorter duration of pregnancy, and associated lighter babies, compared with women without significant reactivation (stillborn: 176 vs 197 days, P ¼ 0.16, and live born: 271 vs 279 days, P ¼ 0.03, respectively). Conclusion Significant reactivation of EBV infection during pregnancy may influence pregnancy duration.

show abstract

Section: Methodsmentioning

confidence: 99%

Epstein–Barr virus infection during pregnancy and the risk of adverse pregnancy outcome

Eskild

Bruu

Stray‐Pedersen

et al. 2005

BJOG

View full text Add to dashboard Cite

show abstract

“…Serological assays that rely on recombinant proteins as antigen are widely used in laboratory diagnostics (Ecker et al, 1996;Farber et al, 1993). As a prerequisite, single immunogenic viral genes have to be cloned into prokaryotic or eukaryotic expression plasmids to produce proteins in bacterial or mammalian cell cultures.…”

Section: Recombinant Protein-based Assaysmentioning

confidence: 99%

Serological assays for emerging coronaviruses: Challenges and pitfalls

2014

View full text Add to dashboard Cite

More than a decade after the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002/2003 the occurrence of a novel CoV termed Middle East respiratory syndrome (MERS) CoV challenges researchers and public health authorities. To control spread and finally contain novel viruses, rapid identification and subsequent isolation of infected individuals and their contacts is of utmost importance. Next to methods for nucleic acid detection, validated serological assays are particularly important as the timeframe for antibody detection is less restricted. During the SARS-CoV epidemic a wide variety of serological diagnostic assays were established using multiple methods as well as different viral antigens. Even though the majority of the developed assays showed high sensitivity and specificity, numerous studies reported on cross-reactive antibodies to antigens from wide-spread common cold associated CoVs. In order to improve preparedness and responsiveness during future outbreaks of novel CoVs, information and problems regarding serological diagnosis that occurred during the SARS-CoV should be acknowledged. In this review we summarize the performance of different serological assays as well as the applicability of the two main applied antigens (spike and nucleocapsid protein) used during the SARS-CoV outbreak. We highlight challenges and potential pitfalls that occur when dealing with a novel emerging coronavirus like MERS-CoV. In addition we describe problems that might occur when animal sera are tested in serological assays for the identification of putative reservoirs. Finally, we give a recommendation for a serological testing scheme and outline necessary improvements that should be implemented for a better preparedness.

show abstract

“…Information on EBV status of EBV infections in a particular disease format is best obtained by assessing of a number of different, additional serological parameters. Enyzme-linked immunosorbent assays (ELISA) have been used to detect antibodies to EBV nuclear antigen (EBNA), early antigen (EA), and viral capsid antigen (VCA) [4][5][6][7][8], and purified EBV-specific proteins [9][10][11][12][13][14][15][16][17][18]. EA antibodies are detected by the immunofluorescence technique in sera of patients with EBV associated diseases, and are usually either not detected or detected at lower levels in sera of healthy sub-jects by the immunofluorescence technique [3].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Antibodies to the Epstein-Barr Virus Immediate Early Gene Product ZEBRA by a New Enzyme-Linked Immunosorbent Assay

Yamauchi¹,

Tachiband²,

Maeda³

et al. 1998

Intervirology

View full text Add to dashboard Cite

For the serodiagnosis of Epstein-Barr virus (EBV) infections, we have developed a new enzyme-linked immunosorbent assay (ELISA) for antibodies to the ZEBRA product of EBV immediate early gene BZLF1. ZEBRA protein fused with glutathione-S-transferase (GST) was expressed in Escherichia coli and purified by affinity chromatography with glutathione-Sepharose 4B. An ELISA sandwich capture system was constructed with the GST-ZEBRA immobilized on plastic microtiter plates which had been coated with a mouse monoclonal antibody to GST. ZEBRA-IgG antibodies in patients’ sera with chronic active EBV infection (CAEBV) and infectious mononucleosis (IM) had, respectively, very high and high titers. Anti-ZEBRA antibodies were also detected at low titers in sera of some healthy controls. ZEBRA-IgM antibodies were detected in sera of patients with IM and CAEBV but not in sera of healthy controls. In sera of patients with CAEBV, the titers of IgG antibodies to ZEBRA correlated with the antibody titers to early antigens obtained with an immunofluorescence assay, but not to EBV nuclear antigens. This ELISA is a useful diagnostic and prognostic test for EBV infection.

show abstract

Serological diagnosis of infectious mononucleosis using three anti-Epstein-Barr virus recombinant ELISAs

Cited by 37 publications

References 11 publications

Epstein–Barr virus infection during pregnancy and the risk of adverse pregnancy outcome

Epstein–Barr virus infection during pregnancy and the risk of adverse pregnancy outcome

Serological assays for emerging coronaviruses: Challenges and pitfalls

Evaluation of Antibodies to the Epstein-Barr Virus Immediate Early Gene Product ZEBRA by a New Enzyme-Linked Immunosorbent Assay

Contact Info

Product

Resources

About